Literature DB >> 11120862

The influence of HLA class I alleles and heterozygosity on the outcome of human T cell lymphotropic virus type I infection.

K J Jeffery1, A A Siddiqui, M Bunce, A L Lloyd, A M Vine, A D Witkover, S Izumo, K Usuku, K I Welsh, M Osame, C R Bangham.   

Abstract

The inflammatory disease human T cell lymphotropic virus type I (HTLV-I)-associated myelopathy (HAM/TSP) occurs in only 1-2% of HTLV-I-infected individuals and is associated with a high provirus load of HTLV-I. We hypothesize that a person's risk of developing HAM/TSP depends upon the efficiency of their immune response to the virus, which differs between individuals because of polymorphism in genes that influence this response. Previously we showed that the possession of HLA-A*02 was associated with a lower risk of HAM/TSP, and with a lower provirus load in healthy carriers of HTLV-I. However, HLA-A*02 did not account for all the observed difference in the risk of HAM/TSP. Here we present evidence, in the same study population in Japan, that HLA-Cw*08 was also associated with disease protection (probability value, two-tailed test = 0.002) and with a lower proviral load in healthy carriers. Possession of the A*02 and/or Cw*08 genes prevented 36% of potential HAM/TSP cases. In contrast, HLA-B*5401 was associated with a higher susceptibility to HAM/TSP (probability value, two-tailed test = 0.0003) and with a higher provirus load in HAM/TSP patients. At a given provirus load, B*5401 appeared to increase the risk of disease. The fraction of HAM/TSP cases attributable to B*5401 was 17%. Furthermore, individuals who were heterozygous at all three HLA class I loci have a lower HTLV-I provirus load than those who were homozygous at one or more loci. These results are consistent with the proposal that a strong class I-restricted CTL response to HTLV-I reduces the proviral load and hence the risk of disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11120862     DOI: 10.4049/jimmunol.165.12.7278

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  82 in total

1.  HLA-Cw7 zygosity affects the size of a subset of CD158b+ natural killer cells.

Authors:  Zaheed Husain; Edward Levitan; Charles E Larsen; Nadeem M Mirza; Souhad Younes; Edmond J Yunis; Chester A Alper; Devendra P Dubey
Journal:  J Clin Immunol       Date:  2002-01       Impact factor: 8.317

2.  Heterozygote advantage fails to explain the high degree of polymorphism of the MHC.

Authors:  Rob J De Boer; José A M Borghans; Michiel van Boven; Can Keşmir; Franz J Weissing
Journal:  Immunogenetics       Date:  2004-01-13       Impact factor: 2.846

3.  MHC polymorphism under host-pathogen coevolution.

Authors:  José A M Borghans; Joost B Beltman; Rob J De Boer
Journal:  Immunogenetics       Date:  2004-01-13       Impact factor: 2.846

Review 4.  Interference with immune function by HTLV-1.

Authors:  P K C Goon; C R M Bangham
Journal:  Clin Exp Immunol       Date:  2004-08       Impact factor: 4.330

Review 5.  The adaptive immune system in diseases of the central nervous system.

Authors:  David C Wraith; Lindsay B Nicholson
Journal:  J Clin Invest       Date:  2012-04-02       Impact factor: 14.808

Review 6.  Neuroimmunity of HTLV-I Infection.

Authors:  Eiji Matsuura; Yoshihisa Yamano; Steven Jacobson
Journal:  J Neuroimmune Pharmacol       Date:  2010-05-02       Impact factor: 4.147

7.  Association between HLA-DQB1 alleles and HAM/TSP patients in Khorasan Province.

Authors:  Amir Reza Tafreshian; Mehdi Etemadi; Reza Farid-Hosseini; Mansoor Salhi; Jalil Tavakkol Afshari
Journal:  Iran J Basic Med Sci       Date:  2014-10       Impact factor: 2.699

8.  Genetic variability in the extracellular matrix protein as a determinant of risk for developing HTLV-I-associated neurological disease.

Authors:  Yasuyuki Nobuhara; Koichiro Usuku; Mineki Saito; Shuji Izumo; Kimiyoshi Arimura; Charles R M Bangham; Mitsuhiro Osame
Journal:  Immunogenetics       Date:  2006-01-10       Impact factor: 2.846

Review 9.  Human T-lymphotropic virus type 1 (HTLV-1): persistence and immune control.

Authors:  Charles R M Bangham
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.490

10.  MHC heterozygosity confers a selective advantage against multiple-strain infections.

Authors:  Dustin J Penn; Kristy Damjanovich; Wayne K Potts
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.